Radko Komers

5.0k total citations
102 papers, 3.6k citations indexed

About

Radko Komers is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Radko Komers has authored 102 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Nephrology, 33 papers in Cardiology and Cardiovascular Medicine and 22 papers in Molecular Biology. Recurrent topics in Radko Komers's work include Renal Diseases and Glomerulopathies (39 papers), Renin-Angiotensin System Studies (24 papers) and Chronic Kidney Disease and Diabetes (21 papers). Radko Komers is often cited by papers focused on Renal Diseases and Glomerulopathies (39 papers), Renin-Angiotensin System Studies (24 papers) and Chronic Kidney Disease and Diabetes (21 papers). Radko Komers collaborates with scholars based in United States, Czechia and Australia. Radko Komers's co-authors include Sharon Anderson, T Oyama, Jessie N. Lindsley, Volker Vallon, Mark E. Cooper, Jana Ždychová, Bei Xu, Phillip Kantharidis, Michal Herman‐Edelstein and Paul Gregorevic and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Radko Komers

96 papers receiving 3.5k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Radko Komers 1.2k 1.2k 786 689 666 102 3.6k
Toshiro Sugimoto 2.1k 1.7× 1.5k 1.2× 607 0.8× 843 1.2× 907 1.4× 100 5.3k
Ming‐Zhi Zhang 1.5k 1.3× 855 0.7× 596 0.8× 487 0.7× 647 1.0× 83 4.1k
Keiji Isshiki 1.7k 1.4× 1.4k 1.1× 698 0.9× 898 1.3× 1.1k 1.7× 73 5.1k
Günter Wolf 1.6k 1.3× 1.5k 1.2× 1.1k 1.4× 352 0.5× 722 1.1× 70 4.5k
Alison J. Cox 1.2k 1.0× 882 0.7× 1.1k 1.4× 262 0.4× 961 1.4× 71 3.6k
Motohide Isono 1.6k 1.3× 1.5k 1.3× 454 0.6× 376 0.5× 589 0.9× 43 3.6k
Colin J. Meyer 3.2k 2.6× 952 0.8× 385 0.5× 436 0.6× 562 0.8× 82 5.2k
Kazunori Utsunomiya 1.3k 1.0× 661 0.6× 560 0.7× 582 0.8× 1.6k 2.5× 152 4.0k
Wendy C. Burns 1.3k 1.1× 931 0.8× 1.1k 1.4× 268 0.4× 1.1k 1.6× 32 3.9k
Zemin Cao 995 0.8× 942 0.8× 1.4k 1.7× 265 0.4× 1.1k 1.6× 53 3.4k

Countries citing papers authored by Radko Komers

Since Specialization
Citations

This map shows the geographic impact of Radko Komers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radko Komers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radko Komers more than expected).

Fields of papers citing papers by Radko Komers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radko Komers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radko Komers. The network helps show where Radko Komers may publish in the future.

Co-authorship network of co-authors of Radko Komers

This figure shows the co-authorship network connecting the top 25 collaborators of Radko Komers. A scholar is included among the top collaborators of Radko Komers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radko Komers. Radko Komers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hendry, Bruce M., Vladimı́r Tesař, Radko Komers, et al.. (2025). WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT. Kidney International Reports. 10(2). S204–S205. 1 indexed citations
2.
Gyarmati, Georgina, et al.. (2024). Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS. JCI Insight. 9(19). 5 indexed citations
3.
Suzuki, Hitoshi, Yusuke Fukao, Tomoyuki Otsuka, et al.. (2024). Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nephrology Dialysis Transplantation. 39(9). 1494–1503. 19 indexed citations
4.
Reily, Colin, Zina Moldoveanu, Tiziano Pramparo, et al.. (2024). Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. American Journal of Physiology-Renal Physiology. 326(5). F862–F875. 12 indexed citations
5.
Trachtman, Howard, Jai Radhakrishnan, Michelle N. Rheault, et al.. (2024). Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney International Reports. 9(4). 1020–1030. 2 indexed citations
6.
Gong, Wu, et al.. (2024). Outcomes of the DUPLEX Trial in Patients with Genetic Focal Segmental Glomerulosclerosis (gFSGS). Journal of the American Society of Nephrology. 35(10S).
7.
Mariani, Laura, Howard Trachtman, Aliza Thompson, et al.. (2024). Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis. American Journal of Kidney Diseases. 85(5). 610–617. 1 indexed citations
8.
Barratt, Jonathan, Hiddo J.L. Heerspink, Muh Geot Wong, et al.. (2023). #4057 SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations
9.
Cosgrove, Dominic, Michael Anne Gratton, Gina Samuelson, et al.. (2023). Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. The Journal of Pathology. 260(3). 353–364. 17 indexed citations
10.
Trachtman, Howard, Rosanna Coppo, Moin A. Saleem, Alex Mercer, & Radko Komers. (2023). Maximizing the value of the open label extension phase of randomized clinical trials. Journal of Nephrology. 36(6). 1561–1563. 3 indexed citations
11.
Suzuki, Hitoshi, Seiji Ueda, Yusuke Fukao, et al.. (2020). Sparsentan Protects Against Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy. Journal of the American Society of Nephrology. 31(10S). 564–564. 1 indexed citations
12.
Trachtman, Howard, Peter J. Nelson, Sharon G. Adler, et al.. (2018). DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology. 29(11). 2745–2754. 129 indexed citations
13.
Vallon, Volker & Radko Komers. (2011). Pathophysiology of the Diabetic Kidney. Comprehensive physiology. 1(3). 1175–1232. 11 indexed citations
14.
Komers, Radko, et al.. (2009). Determination of caveolin-1 in renal caveolar and non-caveolar fractions in experimental type 1 diabetes. Physiological Research. 58(4). 563–568. 9 indexed citations
15.
Komers, Radko, Jessie N. Lindsley, T Oyama, David Cohen, & Sharon Anderson. (2007). Renal p38 MAP kinase activity in experimental diabetes. Laboratory Investigation. 87(6). 548–558. 40 indexed citations
16.
Komers, Radko, et al.. (2005). Gender hormones and the progression of experimental polycystic kidney disease. Kidney International. 68(4). 1729–1739. 76 indexed citations
17.
Komers, Radko, et al.. (2003). Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney International. 63(5). 1776–1784. 40 indexed citations
18.
Komers, Radko & Sharon Anderson. (2000). Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?. Current Opinion in Nephrology & Hypertension. 9(2). 173–179. 5 indexed citations
19.
Komers, Radko & Sharon Anderson. (2000). Optimal strategies for preventing progression of renal disease: Should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?. Current Hypertension Reports. 2(5). 465–472. 3 indexed citations
20.
Komers, Radko & A Vrána. (1998). Thiazolidinediones--tools for the research of metabolic syndrome X.. PubMed. 47(4). 215–25. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiro Sugimoto Breakdown of academic impact, for papers by Ming‐Zhi Zhang Breakdown of academic impact, for papers by Keiji Isshiki Breakdown of academic impact, for papers by Günter Wolf Breakdown of academic impact, for papers by Alison J. Cox Breakdown of academic impact, for papers by Motohide Isono Breakdown of academic impact, for papers by Colin J. Meyer Breakdown of academic impact, for papers by Kazunori Utsunomiya Breakdown of academic impact, for papers by Wendy C. Burns Breakdown of academic impact, for papers by Zemin Cao
Rankless by CCL
2026